麻豆传媒

Roy A. Jensen, M.D. earned his bachelor鈥檚 degree in Biology and Chemistry from Pittsburg State University in 1980. He graduated from Vanderbilt University School of Medicine in 1984, and remained there to complete a residency in Anatomic Pathology and a Surgical Pathology fellowship under the direction of Dr. David L. Page. Following his clinical training he accepted a biotechnology training fellowship at the National Cancer Institute in the laboratory of Dr. Stuart Aaronson. He returned to Vanderbilt in 1991 and was appointed an assistant professor in the Departments of Pathology and Cell Biology. In 1993 Dr. Jensen was appointed as an investigator in the Vanderbilt-Ingram Cancer Center and assumed the management of the Human Tissue Acquisition and Pathology Shared Resource.  Dr. Jensen was promoted to associate professor of Pathology and Cell Biology in 1996, and was appointed as an associate professor of Cancer Biology in 2001.

In 2004, Dr. Jensen returned home to Kansas and was appointed the William R. Jewell, M.D. Distinguished Kansas Masonic Professor, the director of The University of Kansas Cancer Center, the director of the Kansas Masonic Cancer Research Institute, professor of Pathology and Laboratory Medicine, and professor of Anatomy and Cell Biology at the University of Kansas Medical Center. He also holds appointments as a professor in the Department of Molecular Biosciences at the University of Kansas-Lawrence and as professor in Cancer Biology at The University of Kansas Medical Center. Dr. Jensen is currently serving as president of the Association of American Cancer Institutes (AACI) and is a member of several scientific and professional societies including the American Association for Cancer Research, the American Association for the Advancement of Science, the American Society for Cell Biology, the American Society for Investigative Pathology, and the United States and Canadian Academy of Pathology. He currently has over 150 scientific publications and has lectured widely on the clinical and molecular aspects of breast cancer pathology. Dr. Jensen's research interests are focused on understanding the function of BRCA1 and BRCA2 and their role in breast and ovarian neoplasia; and in the characterization of premalignant breast disease both at the morphologic and molecular levels. His laboratory was instrumental in demonstrating the role of BRCA1 in the growth control of normal and malignant cells and in how loss of functional BRCA1 contributes to the development of breast cancer.

Since becoming director of The University of Kansas Cancer Center in 2004, he has recruited a world-class leadership team and successfully led that team in achieving designation for The University of Kansas Cancer Center as a National Cancer Institute designated cancer center.

Scientist Andrew Ewald studies how cells work together, organize and form organs in early development. Cancer cells co-opt these mechanisms to break away from a tumor and form metastatic sites all over the body.

Biologist Karen Guillemin is an internationally recognized expert in microbiology, cell and development biology, and host-microbe systems, and is developing new models to define host-microbe interactions in development and disease. Guillemin examines how hosts and their associated microbial communities shape each other, with the goal of understanding the principles by which complex host-microbe systems function and to learn how they can be manipulated to promote the health of human systems. 

Karen pioneered the use of zebrafish to study host-microbe interactions, including the influence of the gut microbiome on development, metabolism, and immunity.

A fellow in the American Association for the Advancement of Science, she serves as Phillip H. Knight Chair and professor of biology at the University of Oregon in the Institute of Molecular Biology. She has been on the faculty of the UO since 2001 and published more than 100 scientific papers.

Research in the Maguire lab takes a systems physiology approach to studying the mechanisms contributing to neurological and neuropsychiatric diseases, with a focus on epilepsy and mood disorders. Our research has explored the impact of the neuroendocrine system on the comorbidity of epilepsy and depression as well as the role in postpartum depression. Working from the vantage point of synaptic changes, such as GABAergic dysregulation, to circuit dysfunction between the prefrontal cortex and the amygdala, to in vivo changes in excitability and behavior, we have explored many mechanistic levels contributing to neurological and neuropsychiatric diseases. We have incorporated cutting edge tools into our research program, where appropriate, to study the contribution of specific cell types and circuits in mediating physiological and pathological processes. Based on our discovery of neurosteroid-mediated alterations in GABAA receptor subunit expression during pregnancy and the postpartum period and our theory for a potential role in postpartum depression, a company designing neurosteroid-based treatment approaches embarked on a series of successful clinical trials for the treatment of postpartum depression. Our discoveries have also generated two useful mouse models of postpartum depression, leading to a collaboration with SAGE Therapeutics to perform preclinical studies on the underlying mechanisms and treatment options for postpartum depression. Our basic research program is also actively investigating the mechanisms of hypothalamic-pituitary-adrenal (HPA) axis regulation during the peripartum period and the contribution of dysregulation of the HPA axis in abnormal postpartum behaviors. Our research has also discovered a novel mechanism contributing to epilepsy progression and associated comorbidities, involving dysfunction in the regulation of the HPA axis. This work has carved out a niche in the field, establishing our lab as experts in this area. This work also earned two competitive research grants (RO1s) from the National Institutes of Health to fund this work. Our lab is presenting investigating the pathological consequences of seizure-induced activation of the HPA axis, focusing on the role of hypercortisolism in seizure susceptibility and associated comorbidities.

Shannon Conley, Ph.D., is a researcher and faculty member in the Department of Cell Biology at the University of Oklahoma College of Medicine. She has worked in age-related diseases and smooth muscle cell biology for more than 10 years and has published more than 90 research articles. During her graduate and postgraduate training, she gained extensive experience and skill sets in neuronal and vascular diseases in the aging eye. Her early work on vascular and degenerative diseases prompted her to pursue her research interests in vascular smooth muscle cell biology in the aging brain and to establish her sustainable, independent NIH-funded research program. Since obtaining her first faculty position in 2012, one of her greatest pleasures is working one-on-one with students in the lab to help them learn technical, analytical, writing, communication and professional skills. She has mentored students at a variety of levels. Conley earned her doctorate from the Department of Pharmacology and Toxicology at the University of Arizona, and she completed a postdoctoral fellowship in cell biology at the OU College of Medicine. She is a member of the International Society for Cerebral Blood Flow and Metabolism, the American Aging Association, and the Association for Research in Vision and Ophthalmology. She is associate editor of the journal GeroScience.

Sreemathi Logan, Ph.D., is a faculty member in the Department of Biochemistry and Physiology at the University of Oklahoma College of Medicine and a researcher in the Oklahoma Center for Geroscience and Healthy Brain Aging. At the Center for Geroscience, she also directs the Animal Model Development and Behavioral Analysis (AMD-BA) core as part of the Center of Biomedical Research Excellence (CoBRE) grant. Her career in research has encompassed many aspects of aging, including her early work on Alzheimer’s disease in the initial characterization of the 5x FAD model generated by Dr. Robert Vassar at Northwestern University Chicago. The current focus of her research lab is to pursue mechanisms underlying cognitive dysfunction associated with age and neurodegenerative disorders. More specifically, she is interested in the role of astrocyte mitochondrial metabolism and redox status that alter the astrocytic phenotype and increase gliosis during aging. Through her research, she has demonstrated that age-related decline in IGF-1, a neurotrophic factor, impairs cognitive function that correlates with a decline in mitochondrial energy production and increased oxidative stress. Using advanced methodologies, she has made significant advances in addressing and characterizing the heterogeneity in cognitive function that occurs with age. Her lab also has the unique capability of characterizing mice based on their cognitive status (impaired or resilient), which mirrors the inherent susceptibility (or resilience) found in the aging human population. She also performs stereotactic delivery of compounds directly into the hippocampus to investigate localized effects on learning and memory. Logan earned her doctorate in cell biology and completed a postdoctoral fellowship in geriatric medicine, both at the OU College of Medicine.